Published in J Infect Dis on January 07, 2005
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad) | NCT01082341
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis (2012) 1.85
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther (2012) 1.76
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med (2004) 1.70
Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci (2011) 1.70
Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med (2008) 1.65
CD8+ T effector memory cells protect against liver-stage malaria. J Immunol (2011) 1.55
Real-time quantitative reverse transcription PCR for monitoring of blood-stage Plasmodium falciparum infections in malaria human challenge trials. Am J Trop Med Hyg (2012) 1.55
Molecular epidemiology of malaria. Clin Microbiol Rev (2007) 1.53
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One (2008) 1.51
A plant-derived morphinan as a novel lead compound active against malaria liver stages. PLoS Med (2006) 1.49
The relationship between RTS,S vaccine-induced antibodies, CD4⁺ T cell responses and protection against Plasmodium falciparum infection. PLoS One (2013) 1.49
Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One (2011) 1.43
How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malar J (2007) 1.35
Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence. Am J Trop Med Hyg (2006) 1.33
Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PLoS One (2013) 1.33
Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis (2011) 1.30
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun (2006) 1.30
Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. Malar J (2007) 1.29
Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis (2011) 1.28
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One (2011) 1.27
A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine (2011) 1.25
Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am J Trop Med Hyg (2007) 1.20
Comparative evaluation of published real-time PCR assays for the detection of malaria following MIQE guidelines. Malar J (2013) 1.19
Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother (2012) 1.13
Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection. J Infect Dis (2013) 1.12
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis (2014) 1.09
Strain theory of malaria: the first 50 years. Adv Parasitol (2008) 1.09
A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One (2012) 1.07
Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One (2007) 1.06
Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother (2013) 1.05
Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg (2012) 0.99
Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. Ther Clin Risk Manag (2008) 0.99
Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med (2015) 0.97
The dynamics of naturally acquired immunity to Plasmodium falciparum infection. PLoS Comput Biol (2012) 0.97
Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One (2013) 0.95
Malaria diagnostics in clinical trials. Am J Trop Med Hyg (2013) 0.95
Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun (2008) 0.95
Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc Biol Sci (2010) 0.92
Identification of targets of CD8⁺ T cell responses to malaria liver stages by genome-wide epitope profiling. PLoS Pathog (2013) 0.91
Ad35.CS.01-RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults. PLoS One (2015) 0.88
Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight (2017) 0.86
Measurement of parasitological data by quantitative real-time PCR from controlled human malaria infection trials at the Walter Reed Army Institute of Research. Malar J (2014) 0.86
Viral vector vaccines make memory T cells against malaria. Immunology (2007) 0.86
Tailoring a Combination Preerythrocytic Malaria Vaccine. Infect Immun (2015) 0.84
A nested real-time PCR assay for the quantification of Plasmodium falciparum DNA extracted from dried blood spots. Malar J (2014) 0.84
Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl Trop Dis (2016) 0.83
Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection. Am J Trop Med Hyg (2015) 0.82
Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge. PLoS One (2014) 0.82
Decreased growth rate of P. falciparum blood stage parasitemia with age in a holoendemic population. J Infect Dis (2013) 0.82
Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Vaccine (2015) 0.80
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malar J (2015) 0.80
Time-to-infection by Plasmodium falciparum is largely determined by random factors. BMC Med (2015) 0.79
Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines. Am J Trop Med Hyg (2015) 0.79
Density-dependent blood stage Plasmodium falciparum suppresses malaria super-infection in a malaria holoendemic population. Am J Trop Med Hyg (2013) 0.78
Cross-reactive immune responses as primary drivers of malaria chronicity. Infect Immun (2013) 0.78
Discovery of Dual-Stage Malaria Inhibitors with New Targets. Antimicrob Agents Chemother (2015) 0.77
Synergism from combinations of infection-blocking malaria vaccines. Malar J (2013) 0.77
A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine. PLoS One (2016) 0.76
The High Blood Pressure-Malaria Protection Hypothesis. Circ Res (2016) 0.76
Building better T-cell-inducing malaria vaccines. Immunology (2005) 0.76
Malaria and hypertension. Another co-evolutionary adaptation? Front Cell Infect Microbiol (2014) 0.76
Current therapies and future possibilities for drug development against liver-stage malaria. J Clin Invest (2016) 0.75
Assessment of the Plasmodium falciparum pre-erythrocytic antigen UIS3 as a potential candidate for a malaria vaccine. Infect Immun (2016) 0.75
Profiling the host response to malaria vaccination and malaria challenge. Vaccine (2015) 0.75
The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection. PLoS Comput Biol (2017) 0.75
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines (Basel) (2017) 0.75
Multiplication rate variation in the human malaria parasite Plasmodium falciparum. Sci Rep (2017) 0.75
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med (2004) 6.46
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet (2012) 3.31
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Risk factors for femicide in abusive relationships: results from a multisite case control study. Am J Public Health (2003) 3.23
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol (2007) 3.18
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 3.04
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet (2002) 2.87
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals. Am J Respir Crit Care Med (2009) 2.80
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg (2005) 2.77
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis (2011) 2.71
Quantitative detection of Plasmodium falciparum DNA in saliva, blood, and urine. J Infect Dis (2009) 2.64
Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc Natl Acad Sci U S A (2008) 2.62
Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun (2009) 2.57
Identifying recent adaptations in large-scale genomic data. Cell (2013) 2.57
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One (2009) 2.49
Continued decline of malaria in The Gambia with implications for elimination. PLoS One (2010) 2.47
Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar J (2006) 2.39
Haptoglobin genotypes are not associated with resistance to severe malaria in The Gambia. Trans R Soc Trop Med Hyg (2002) 2.39
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol (2010) 2.25
Human genetic susceptibility to infectious disease. Nat Rev Genet (2012) 2.25
Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis (2011) 2.24
Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology (2003) 2.23
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin (2010) 2.12
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun (2011) 2.11
Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect Immun (2009) 2.08
Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis (2008) 2.05
Malaria impairs resistance to Salmonella through heme- and heme oxygenase-dependent dysfunctional granulocyte mobilization. Nat Med (2011) 2.04
Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol (2005) 2.03
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun (2013) 1.95
Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med (2012) 1.94
Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants. Sci Transl Med (2011) 1.94
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther (2011) 1.92
Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS (2002) 1.92
Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease. Sci Transl Med (2010) 1.90
Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis (2012) 1.85
Hyperinvasive neonatal group B streptococcus has arisen from a bovine ancestor. J Clin Microbiol (2004) 1.83
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis (2012) 1.82
Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol (2011) 1.80
A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin. J Infect Dis (2012) 1.79
Malaria vaccine developments. Lancet (2004) 1.77
Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol (2005) 1.76
Effective induction of high-titer antibodies by viral vector vaccines. Nat Med (2008) 1.76
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther (2012) 1.76
Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun (2002) 1.75
A decline in the incidence of invasive non-typhoidal Salmonella infection in The Gambia temporally associated with a decline in malaria infection. PLoS One (2010) 1.72
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology (2003) 1.72
Progression of Plasmodium berghei through Anopheles stephensi is density-dependent. PLoS Pathog (2007) 1.71
A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med (2004) 1.70
Hybrid Vibrio vulnificus. Emerg Infect Dis (2005) 1.68
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau. Malar J (2009) 1.63
Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol (2006) 1.62